Mesa Laboratories Inc (MLAB) company profile
Close on Nov 13, 2026Market cap $777.88MP/E 120.9Yield 0.46%
About Mesa Laboratories
Industrial Instruments For Measurement, Display, and Control, SIC 3823
Mesa Laboratories, Inc. designs and manufactures life sciences tools and quality control solutions for regulated applications. The company operates through four primary divisions: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Its product offerings encompass biological and chemical indicators, genetic analysis instruments, automated systems for protein analysis and peptide synthesis, continuous monitoring systems, and calibration instruments. Mesa also provides maintenance, testing, and calibration services. It serves customers in the pharmaceutical, healthcare, medical device, dental, and academic sectors.
The company conducts manufacturing operations across facilities in the United States and Europe, including sites in Colorado, Montana, California, Arizona, Germany, and Sweden. Mesa distributes products globally through direct sales personnel in North America, Europe, and the Asia Pacific region, as well as through independent distributors. It employs 717 individuals, including roughly 450 workers located domestically. Mesa Laboratories maintains its corporate headquarters in Lakewood, Colorado.
Summary of the business section of Mesa Laboratories's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Mesa Laboratories Inc
- Founded
- 1982
- Headquarters
- Lakewood, CO
- Address
- 12100 W 6th Ave 80228
- Phone
- (303) 987-8000
- Website
- mesalabs.com
- Employees
- 717, Mar 31, 2026
- Industry
- Industrial Instruments For Measurement, Display, and Control
- Incorporated in
- Colorado
- Fiscal year ends
- March 31
- Auditor
- Baker TillyLLP, Los Angeles, California
Stock & identifiers
- Ticker
- MLAB
- Exchange
- Nasdaq
- IPO date
- Feb 29, 1984
- Shares outstanding
- 6M, Aug 3, 2026
- Public float
- $358.00M, Sep 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 724004
- CUSIP
- 59064R109
- ISIN
- US59064R1095
- FIGI
- BBG000BP3PW7
- Share class FIGI
- BBG001S5T762
- LEI
- 549300ZCG738WLX8ZW79
- EIN
- 84-0872291
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sanket Shah | General Counsel | – |
| Siddhartha Kadia | President and CEO | 7,093 |
| Lyndsey Elizabeth Crennen | CAO | 2,020 |
| Brian David Archbold | SVP Operations | 6,377 |
| John Sakys | CFO | 19,835 |
| Gary M. Owens | President and CEO | 64,135 |
| John James Sullivan | Director | 64,528 |
| R. Tony Tripeny | Director | 6,298 |
| Shiraz Shabanali Ladiwala | Director | 12,333 |
| Jennifer Sadie Alltoft | Director | 7,662 |
| Mark Christopher Capone | Director | 6,213 |
| Shannon Hall | Director | 6,973 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $6.64M | $516.20K | $2.33M | $37 | $35 |
| FY2025 | $6.60M | $7.94M | $2.28M | $50 | $33 |
| FY2024 | $5.44M | $78.00K | $1.78M | $46 | $43 |
| FY2023 | $5.19M | -$3.60M | $1.48M | $72 | $46 |
| FY2022 | $18.08M | $16.81M | $1.45M | $105 | $66 |
| FY2021 | $2.56M | $9.55M | $927.47K | $108 | $169 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Gary Owens Former CEO and President | $808.85K | $4.70M | $1.12M | $14.35K | $6.64M | +1% |
| John Sakys VP and Chief Financial Officer | $498.39K | $1.55M | $408.75K | $14.26K | $2.47M | +2% |
| Brian Archbold SVP of Operations and Continuous Improvement | $436.96K | $1.40M | $331.25K | $14.23K | $2.18M | +2% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of March 31, 2026, we had 717 employees (including approximately 450 domestic employees), of whom 347 are employed for manufacturing and quality assurance, 99 for research and development and engineering, 179 for sales and marketing, and 92 for administrative functions.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?